Is it Time for a National Network of Valve Centers? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH

Size: px
Start display at page:

Download "Is it Time for a National Network of Valve Centers? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH"

Transcription

1 Is it Time for a National Network of Valve Centers? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH 10

2 Potential Conflict of Interest Disclosure Board of Trustees American College of Cardiology Writing Committee Multi-Society National Systems of Care Co- PI of COAPT Trial of Abbott Vascular Steering Committee Intrepid Trial of Medtronic Co-PI of the PARTNER 3 Trial of Edwards Lifesciences

3 2,100 1,150 Cath Labs Cardiac Surgery Programs TAVR Programs MitraClip Programs

4 This is Your Frail, Elderly Father! How many of the 2,100 Cath Labs in the US Should be Treating Him?

5 This Is Your Brother Thickened Leaflets aneurysmal pockets Redundant elongated chords Bileaflet prolapse and billowing Massively dilated annulus Atrialized attachment of posterior leaflet Often highly calcified annulus How Many of the 1,150 Cardiac Surgery Programs Can Repair This Valve? How Many of the 272 Cath Labs Performing MitraClip Realize This is Not a Good MitraClip Case? Barlow s Myxoid Degeneration 5

6 This is Your 90 Year Old Mother With Severe AS with LVOT Ca++ and MAC How Many of the 560 TAVR Programs Would You Let Her be Treated In?

7 2017 AATS/ACC/ASE/SCAI/STS Expert Consensus System of Care Draft Documents (Operator and Institutional TAVR Requirements and Optimizing Care for VHD Patients) 7

8 Misconceptions About a Valve Network It s all about TAVR It s an exclusive club It will limit access to care

9 National Systems of Care Cancer Trauma Stroke Bariatric Surgery STEMI /2007 NIH American College of Surgeons Brain Attack Coalition American Society of Bariatric Surgery American College of Surgeons American College of Cardiology (D2B Alliance) American Heart Association (Mission: Lifeline)

10 National Systems of Care NIH Cancer Centers Basic Laboratory Cancer Center Cancer Centers Comprehensive Cancer Center ACS Trauma Centers Level I Level II Level III Level IV Brain Attack Coalition Stroke Centers Acute Stroke- Ready hospital Primary Stroke Center Comprehensive Stroke Center ASBS ACS Bariatric Centers Bariatric Surgery Center of Excellence ACC/ AHA STEMI STEMI-referral hospital (non-pci capable) STEMI-receiving hospital (PCI-capable)

11 Stroke Systems of Care Comprehensive Primary ASRH Brain Attack Coalition

12 National Valve System of Care

13 Systems of Care for VHD Rationale The cost and complexity of diagnosis and treatment of VHD are increasing. It is not feasible for all cardiac centers to provide the full suite of resources, infrastructure and expertise to care for patients across the entire spectrum of VHD. The guiding principle is to optimize the care of the individual patient by providing access to the right care at the right place and time while respecting his/her preferences and values.

14

15 ESC/EACTS Comprehensive Heart Valve Centre Standards Consideration of the volume-outcome relationship for surgical and transcather procedures is a complex, nuanced and challenging process. Ability to demonstrate good results is more important than mandating volume targets. It is likely that [good outcomes for MV surgery] will not be attained without high individual surgeon and centre volume. Large registries are expected to inform future guidance on minimal [TAVR] volumes Chambers JB et al. EHJ 2017:38:

16 ESC/EACTS Comprehensive Heart Valve Centre Standards Minimum Heart valve clinic Multi-modality imaging Procedures available MDT Processes Data review Procedures TAVR, Mitral Clip All HV replacements MVRp, TVRp Surgery for aortic root and ascending aorta AF ablation Links with other centers Chambers JB et al. EHJ 2017:38:

17 A Spoke-and-Hub or Tiered System of Care for Patients with Valvular Heart Disease? Primary Valve Center PVC Comprehensive Valve Center CVC PVC

18 Comprehensive (Level I) Valve Center TAVR TF BAV TAVR alternative access Valve-in-valve procedures MitraClip Paravalvular leak closure PBMV Isolated AVR Valve-sparing aortic root procedures AVR/Myomectomy Root enlargement with AVR Mitral repair for primary MR (P2 pathology) Interventional procedures Surgical procedures Mitral repair for complex primary MR (Barlow s and bileaflet prolapse) Multivalve operations Re-operative valve surgery Isolated tricuspid valve repair or replacement Primary (Level II) Valve Center TAVR TF BAV Isolated AVR Mitral repair for primary MR (P2 pathology)

19 Optimal Outcomes Access To Care

20 Considerations Quality Access Mortality Morbidity Durability Cost Heart Valve Centers Competition, Restricted Referral Lines, COI, AMC vs. Community, Cultures, Payment Models Disparities Geography Wait Times Follow-Up Courtesy P. O Gara

21 Questions Does This Make Sense? Is there a volume outcome relationship for medical procedures? Is volume an appropriate surrogate for quality? How do you balance quality outcomes with access to care? What are the barriers of access to care Can every center treat every patient and do it well?

22 INSIDE OUTSIDE

23

24 Premises There is a volume outcome relationship in medical procedures The more complex the procedure, the greater that relationship The principle is not only about the performance of the procedure but also about the care ecosystem: Diagnostic/imaging expertise Multi-disciplinary team/shared decision-making Patient selection Post-procedure care All this has to be balanced against adequate access to care

25 Outcome Medical Conditions and Procedures for Which a Volume-Outcome Association Has Been Shown MI, CVA, Heart Failure, Pneumonia CABG, AAA Repair, CEA MVRR, AVR PCI, ICD TAVR 10 Volume Pledge Procedures Volume

26

27

28

29

30

31

32

33

34

35 Primary MR Repair in NY State Wide variability Median volume = 10 Higher surgeon volumes associated with better outcomes Re-operation less common with > 25 repairs per year Chikwe J et al. JACC 2017; 69:

36 Criteria MV surgery volumes (surgeon and center) Expert peri-procedural imaging Transparency regarding outcomes: repair rates, mortality, stroke, durability

37 Standards for MV Repair for Primary MR Outcome Rate Mortality < 1% Major Complication < 2% Repair rate > 90% (> 95% for P2 prolapse) Residual MR > 2+ < 5% at 5 years Re-operation rate PMVL < 1% per year AMVL < 2% per year Chambers JB et al. EHJ 2017:38:

38 AHA/ACC 2017 Valve Disease Guideline Recommendation COR LOE MV repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with preserved LV function (LVEF >60% and LVESD <40 mm) in whom the likelihood of a successful and durable repair without residual MR is >95% with an expected mortality <1% when performed at a Heart Valve Center of Excellence IIa B Nishimura RA et al. JACC 2017 doi: /j.jacc

39

40 Dying During or Immediately After TAVR With experience (case volume) the risk of dying is reduced from 3.57% to 2.15%.

41 Of index TAVR procedures, 663 (4.1%), 3067 (18.9%), and (77.0%) were performed at low-, medium-, and high-volume hospitals, respectively. Thirty-day readmission rates were significantly lower in high-volume compared with medium-volume (adjusted odds ratio, 0.76; 95%CI, ; P <.001) and low-volume (adjusted odds ratio, 0.75; 95%CI, ; P =.007) hospitals Khera et al. JAMA Cardiol. 2017;2(7):

42 Sites Participating in the STS/ACC TVT Registry TAVR MitraClip - 212

43 TAVR Centers in US Alaska: 1 Hawaii: Centers

44 Sites Enrolled in TVT Registry New Sites Added Each Year

45 TAVR

46 Valve Centers/Million Population US Germany Japan Canada UK

47 Dallas Fort Worth Heart Surgery 2016 N=6,456 Programs =40 TAVR N=10

48 A Successful Pilot Hub and spoke Shared protocols, best practices Mentoring Communication

49 Registry Sustainability Fit-to-Purpose Infrastructure Shared Benefits of Multi-Stakeholder Partnerships Databases/Registries ACC NCDR CathPCI ICD IMPACT LAAO AF Ablation PVI STS National Database STS ACS STS CHD STS Thoracic Surgery Joint STS and ACC TVT Aortic TVT Mitral TVT Tricuspid Tier Criteria Case mix Volume and Outcomes Research Infrastructure IRB/Contracting Efficiency Clinical Infrastructure Dataset Needs vs. Capabilities ACCF/STS Tiered Site Certification* *Sites apply for certification level desired for each database. Free to use certification level for each database in marketing. Dataset Complexity & Need for Multi- Stakeholder Support John Laschinger FDA CDRH 49

50

51 Goal of Specialized Valve Center Care Optimize the care of the individual patient by insuring access to the right care, in the right place, at the right time while respecting his/her values and preferences

52 Underlying Principles for Development of a Valve System of Care Optimize the care of the patient with valvular heart disease Increasing complexities of diagnosis and therapy require increasing levels of experience and expertise. Institutional commitment to excellence in care with the provision of appropriate resources to provide this care The Heart Valve Team utilizing a multidisciplinary approach Shared decision making with patient choice should be a primary goal, with clarity to the consumer

53 Underlying Principles for Development of a Valve System of Care Participation in national registries and research trials Participation in quality improvement initiatives On-going analysis of process and outcomes Transparency of outcomes-public reporting On-going education of the valve team as well as to the lines of referral

54 If recommended thresholds for operator and site TAVR volumes are instituted, there will be a dramatic reduction in the number of hospitals providing TAVR Current After Thresholds Source: FY2016 MedPAR 45% # TAVR hospitals reduced from 475 in 2016, to 263 after thresholds Analysis By Edwards Lifesciences

55 What This Is About Not every center can do everything well A rising tide floats all boats

56 Is It Time For Valve Centers of Excellence? Summary The best initial system is probably a tiered system of valve centers Valve centers need to have commitment to structure, processes and outcomes There is a similar initiative in Europe This isn t just about performing a procedure It s about a comprehensive approach to treating a disease that maximizes the chance of a patient getting the right procedure at the right place at the right time with the best possible outcome

57 Is it Time for a National Network of Valve Centers?

2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease

2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease 2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease Patrick T. O Gara, MD BWH Heart and Vascular Center Professor of Medicine, Harvard Medical School Disclosures NHLBI CTSN Co-chair

More information

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,

More information

Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.

Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S. ACC 2015 LBCT Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S. A report from the STS/ACC TVT Registry Paul Sorajja, MD, Saibal Kar, MD, Amanda Stebbins,

More information

Surgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan

Surgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan Surgical AF Ablation : Lesion Sets and Energy Sources What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan Disclosures Consultant/Advisory Board: Abbott, Edwards Lifesciences

More information

Clinical Practice Guidelines and the Under Treatment of Concomitant AF Vinay Badhwar, MD

Clinical Practice Guidelines and the Under Treatment of Concomitant AF Vinay Badhwar, MD Clinical Practice Guidelines and the Under Treatment of Concomitant AF Vinay Badhwar, MD Gordon F. Murray Professor and Chairman Department of Cardiovascular & Thoracic Surgery WVU Heart and Vascular Institute

More information

Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center

Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock

More information

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,

More information

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC NATURAL HISTORY OF MITRAL REGURGITATION Abdallah El Sabbagh et al. JIMG 2018;11:628-643 TREATMENT OPTIONS SURGERY REPAIR REPLACEMENT PERCUTANEOUS INTERVENTIONS

More information

Emerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX

Emerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX Emerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX Conflict of Interest Disclosure Abbott Vascular- Co PI COAPT Trial Medtronic- Executive Committee

More information

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial

More information

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,

More information

TAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion

TAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion TAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion Moderator: Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular

More information

Next Generation Therapies: Aortic, Mitral and Beyond

Next Generation Therapies: Aortic, Mitral and Beyond Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:

More information

Cardiac Valve/Structural Therapies

Cardiac Valve/Structural Therapies Property of Dr. Chad Rammohan Cardiac Valve/Structural Therapies Chad Rammohan, MD FACC Medical Director, El Camino Hospital Cardiac Catheterization Lab Director, Interventional and Structural Cardiology,

More information

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators ACC Late Breaking Clinical Trials March 16,

More information

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Disclosures: GE stock, Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Athena Poppas, MD FACC Past ACC Scientific Sessions Chair, ACC Board

More information

CARDIOLOGY GRAND ROUNDS

CARDIOLOGY GRAND ROUNDS CARDIOLOGY GRAND ROUNDS Presentation: Mitral Disease Speakers: Robert S. Farivar, MD, PhD Chief, Cardiothoracic Surgery, Abbott Northwestern Hospital Chairman, Allina Cardiothoracic; Minneapolis Heart

More information

MitraClip: Why, How, and For Whom?

MitraClip: Why, How, and For Whom? MitraClip: Why, How, and For Whom? Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief, JAMA Cardiology

More information

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New

More information

In Process, Unpublished STS/ACC TVT Registry Manuscripts

In Process, Unpublished STS/ACC TVT Registry Manuscripts In Process, Unpublished STS/ACC TVT Registry Manuscripts The following pages list current research and publications proposals that have been recently approved, are under analysis, are under manuscript

More information

Update on Transcatheter Mitral Valve Repair and Replacment

Update on Transcatheter Mitral Valve Repair and Replacment Update on Transcatheter Mitral Valve Repair and Replacment Vinod H. Thourani, MD Professor of Surgery Chair, Department of Cardiac Surgery Medstar Heart and Vascular Washington Hospital Center Georgetown

More information

In Process, Unpublished STS/ACC TVT Registry Manuscripts

In Process, Unpublished STS/ACC TVT Registry Manuscripts In Process, Unpublished STS/ACC TVT Registry Manuscripts The following pages list current research and publications proposals that have been recently approved, are under analysis, are under manuscript

More information

Mitral Regurgitation

Mitral Regurgitation Mitral Regurgitation Focus on Percutaneous Repair Steven J. Yakubov, MD FACC FSCAI System Chief, Structural Heart Diseaese, OhioHealth John H. McConnell Chair of Advanced Structural Heart Disease Medical

More information

What s New in the Guidelines for Surgical Ablation for Atrial Fibrillation?

What s New in the Guidelines for Surgical Ablation for Atrial Fibrillation? What s New in the Guidelines for Surgical Ablation for Atrial Fibrillation? Vinay Badhwar, MD Gordon F. Murray Professor and Chairman Department of Cardiovascular & Thoracic Surgery West Virginia University

More information

Transcatheter Valve Replacement: Current State in 2017

Transcatheter Valve Replacement: Current State in 2017 Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP

More information

National Cardiovascular Data Registry

National Cardiovascular Data Registry National Cardiovascular Data Registry Young and Early Career Investigators ACC/AGS/NIA Multimorbidity in Older Adults with Cardiovascular Disease Workshop Ralph Brindis, MD MPH Senior Medical Officer,

More information

Valvular Intervention

Valvular Intervention Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone

More information

THE VALVE CLINIC VALVE CONFERENCE

THE VALVE CLINIC VALVE CONFERENCE VALVE CLINIC THE VALVE CLINIC Houston Methodist DeBakey Valve Clinic combines outstanding clinical care, advanced imaging and surgical excellence to offer coordinated evaluation and treatment options for

More information

Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute

Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine

More information

Transcatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health

Transcatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health Transcatheter Mitral Innovations, Part II Michael Mack, M.D. Baylor Scott & White Health Conflict of Interest Disclosure Co-PI of the COAPT Trial of MitraClip sponsored by Abbott Vascular Uncompensated

More information

Organic mitral regurgitation

Organic mitral regurgitation The best in heart valve disease Organic mitral regurgitation Ewa Szymczyk Department of Cardiology Medical University of Lodz, Poland I have nothing to declare Organic mitral regurgitation leaflet abnormality

More information

Clinical & Practical Aspects of Establishing a Successful Heart & Valve Clinic

Clinical & Practical Aspects of Establishing a Successful Heart & Valve Clinic Clinical & Practical Aspects of Establishing a Successful Heart & Valve Clinic Marci S. Damiano, RN, MSN Coordinator of the Center for Valvular Heart Disease Division of Cardiology, Department of Medicine

More information

Establishing an Outreach Referral Network

Establishing an Outreach Referral Network Establishing an Outreach Referral Network Rheumatic Fever 15.000.000 people around the world, Children and young adults, 500.000 deaths /year Thousands desabilities Risk Factor Under development Prevalence

More information

Low Gradient Severe? AS

Low Gradient Severe? AS Low Gradient Severe? AS Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Institut Universitaire de Cardiologie et de Pneumologie de Québec / Québec Heart

More information

Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI

Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate

More information

MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification. Rheumatic Mitral Stenosis 76yo male

MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification. Rheumatic Mitral Stenosis 76yo male MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification David S Rubenson MD FACC FASE Founding Director, Cardiac Non-Invasive Laboratory Scripps Clinic Medical Group number 1 Rheumatic Mitral Stenosis

More information

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? John D. Carroll, MD Professor, Director of Interventional Cardiology and Co-Medical Director of the Cardiac and Vascular Center, University of Colorado

More information

Understanding the guidelines for Interventions in MR. Ali AlMasood

Understanding the guidelines for Interventions in MR. Ali AlMasood Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe

More information

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine

More information

Valvular Heart Disease

Valvular Heart Disease Valvular Heart Disease B K Singh, MD, FACC Disclosures: None 1 CARDIAC CYCLE S2 S2=A2P2 S1=M1T1 S4 S1 S3 2 JVP Carotid S1 Slitting of S2 S3 S4 Ejection click Opening snap Dynamic Auscultation What is the

More information

Vinod H. Thourani, MD, FACC, FACS

Vinod H. Thourani, MD, FACC, FACS Considering SAVR in the TAVR era: Surgical Implications of TAVR Vinod H. Thourani, MD, FACC, FACS Professor of Cardiothoracic Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown

More information

Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical. The Houston Aortic Symposium February 23-25, 2017

Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical. The Houston Aortic Symposium February 23-25, 2017 James S. Gammie, MD Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical The Houston Aortic Symposium February 2-25, 2017 Disclosure Statement of Financial Interest Within

More information

When Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea

When Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea When Should We Consider TAVI Procedure in Korea (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea Aortic Stenosis in Korea Rapidly increasing valve disease in Korea Still low incidence

More information

Clinical Value of 3D Echo: Volumes and Valves

Clinical Value of 3D Echo: Volumes and Valves Clinical Value of 3D Echo: Volumes and Valves James D. Thomas, M.D., F.A.C.C. Cardiovascular Imaging Center Department of Cardiology Cleveland Clinic Foundation Cleveland, Ohio, USA Conflicts: None 3D2011:1

More information

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC MitraClip Therapy Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Program Director, Interventional Cardiology Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

More information

Valvular Guidelines: The Past, the Present, the Future

Valvular Guidelines: The Past, the Present, the Future Valvular Guidelines: The Past, the Present, the Future Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief,

More information

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional

More information

Spotlight on Valvular Heart Disease Guidelines

Spotlight on Valvular Heart Disease Guidelines Spotlight on Valvular Heart Disease Guidelines Aortic Valve Disease Raphael Rosenhek Department of Cardiology Medical University of Vienna Palermo, April 26 th 2018 1998 2002 2006 2007 2008 2012 2014 2017

More information

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat

More information

Transcatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis

Transcatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis Transcatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis John Webb MD Director interventional cardiology, St Paul s Hospital McLeod Professor of

More information

Transcatheter Mitral Valve for fmr: The Era of Too Many Options

Transcatheter Mitral Valve for fmr: The Era of Too Many Options Transcatheter Mitral Valve for fmr: The Era of Too Many Options Isaac George, M.D. Surgical Director, Structural Heart & Valve Center Assistant Professor of Surgery Columbia University Medical Center Disclosure

More information

Primary Mitral Regurgitation

Primary Mitral Regurgitation EURO VALVE Madrid News from Valves Guidelines 2012: What s new and Why? Primary Mitral Regurgitation Luc A. Pierard, MD, PhD Professor of Medicine Head of the Department of Cardiology Heart Valve Clinic,

More information

Burden of Mitral Regurgitation (MR) in the US Why is This Important?

Burden of Mitral Regurgitation (MR) in the US Why is This Important? Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence

More information

Indication, Timing, Assessment and Update on TAVI

Indication, Timing, Assessment and Update on TAVI Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical

More information

Aortic Stenosis: Background

Aortic Stenosis: Background Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic

More information

Mitral Valve Disease, When to Intervene

Mitral Valve Disease, When to Intervene Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages

More information

Low Gradient AS: Multi-Imaging Modalities

Low Gradient AS: Multi-Imaging Modalities Low Gradient AS: Multi-Imaging Modalities Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Institut Universitaire de Cardiologie et de Pneumologie de

More information

Get Ready for Percutaneous Mitral Valve Approaches

Get Ready for Percutaneous Mitral Valve Approaches Get Ready for Percutaneous Mitral Valve Approaches Paul A. Grayburn, MD Baylor Scott and White Healthcare System The Heart Hospital Baylor Plano and Baylor Heart and Vascular Hospital Dallas, TX HOPE Unmet

More information

Valve Disease. Valve Surgery. Total Volume. In 2016, Cleveland Clinic surgeons performed 3039 valve surgeries.

Valve Disease. Valve Surgery. Total Volume. In 2016, Cleveland Clinic surgeons performed 3039 valve surgeries. Valve Surgery Total Volume 1 1 Volume 35 3 5 15 1 5 1 13 1 N = 773 5 79 15 93 1 339 In 1, surgeons performed 339 valve surgeries. surgeons have implanted more than 1, bioprosthetic aortic valves since

More information

Mitral Valve Surgery: Lessons from New York State

Mitral Valve Surgery: Lessons from New York State Mitral Valve Surgery: Lessons from New York State Joanna Chikwe, MD Professor of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai Chairman & Program Director Department of Cardiovascular

More information

Joseph E. Bavaria, M.D. Roberts Measy Professor and Vice Chief CardioVascular Surgery Director: Thoracic Aortic Surgery Program University of

Joseph E. Bavaria, M.D. Roberts Measy Professor and Vice Chief CardioVascular Surgery Director: Thoracic Aortic Surgery Program University of Joseph E. Bavaria, M.D. Roberts Measy Professor and Vice Chief CardioVascular Surgery Director: Thoracic Aortic Surgery Program University of Pennsylvania, USA North American Valve Repair, Philadelphia

More information

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai

More information

Prognostic Impact of FMR

Prognostic Impact of FMR Secondary Mitral Valve Regurgitation in Heart Failure, Age 60 Years From Medical Therapy to Surgical Repair to Transcatheter Intervention The Interventionalist s View Samin K Sharma, MD, FACC, FSCAI Director

More information

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve

More information

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries

More information

Gender Differences in Valvular Heart Disease. Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences

Gender Differences in Valvular Heart Disease. Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences Gender Differences in Valvular Heart Disease Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences Obstacles Interest in gender differences is a relatively new phenomenon Registries/RCT

More information

TAVR or SAVR: Beyond the STS Score

TAVR or SAVR: Beyond the STS Score TAVR or SAVR: Beyond the STS Score Juan Crestanello, MD Division of Cardiac Surgery Lakshmi Prasad Dasi, PhD Department of Biomedical Engineering The Ohio State University Wexner Medical Center 1 Disclosures

More information

Appropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK

Appropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner

More information

Asymptomatic Valvular Disease:

Asymptomatic Valvular Disease: Asymptomatic Valvular Disease: Can Echocardiography Help You Decide When to Intervene? Neil J. Weissman, MD MedStar Health Research Inst at MedStar Washington Hospital Center & Professor of Medicine Georgetown

More information

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division

More information

7 th Conference of Transcatheter Heart Valve Therapies

7 th Conference of Transcatheter Heart Valve Therapies 7 th Conference of Transcatheter Heart Valve Therapies May 18-19, 2018, Athens Hilton Athens, Greece Course Directors Stratis Pattakos MD Konstantinos Spargias MD Panos Vardas MD Co-Directors Nick Bouboulis

More information

NY STATE NPA 33 rd Annual Conference TAVR & Structural Heart Update

NY STATE NPA 33 rd Annual Conference TAVR & Structural Heart Update NY STATE NPA 33 rd Annual Conference TAVR & Structural Heart Update October 21, 2017 Rose Hansen DNP Structural Heart Coordinator Gates Vascular Institute, Buffalo NY TAVR Update: Objectives 1. Understand

More information

Operate NOT every BAV aorta at 5 cm. Markus Schwerzmann, MD

Operate NOT every BAV aorta at 5 cm. Markus Schwerzmann, MD Operate NOT every BAV aorta at 5 cm Markus Schwerzmann, MD Historical perspective Curr Probl Cardiol 2008;33:203-77 Yale Center for thoracic aortic disease database (2000): 1600 patients with a thoracic

More information

Assessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University

Assessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University Assessment and Preparation of Patients with TAVI Rob Tanzola Associate Professor, Queen s University My patient has aortic stenosis and needs non-cardiac surgery Should (s)he get a TAVI? Rob Tanzola Associate

More information

Percutaneous Mitral Valve Repair

Percutaneous Mitral Valve Repair Percutaneous Mitral Valve Repair Policy Number: Original Effective Date: MM.06.027 08/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/01/2017 Section: Surgery Place(s)

More information

Valvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD

Valvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD Valvular Heart Disease Transcatheter Valve Therapies October 2016 Brian Whisenant MD Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement

More information

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant

More information

Percutaneous mitral valve repair: current techniques and results

Percutaneous mitral valve repair: current techniques and results Percutaneous mitral valve repair: current techniques and results Ted Feldman, M.D., FSCAI, FACC Angioplasty Summit April 25-27 th th 2007 Seoul, Korea Ted Feldman MD, FACC, FSCAI Disclosure Information

More information

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

Late secondary TR after left sided heart disease correction: is it predictibale and preventable Late secondary TR after left sided heart disease correction: is it predictibale and preventable Gilles D. Dreyfus Professor of Cardiothoracic surgery Nath J, et al. JACC 2004 PREDICT Incidence of secondary

More information

Mitral Valve Reference Center. Ariana González Gómez Heart Valve Clinic. University Hospital Ramón y Cajal. Madrid. Spain.

Mitral Valve Reference Center. Ariana González Gómez Heart Valve Clinic. University Hospital Ramón y Cajal. Madrid. Spain. Mitral Valve Reference Center Ariana González Gómez Heart Valve Clinic. University Hospital Ramón y Cajal. Madrid. Spain. Introduction MICLIP STUDY Prevalence of MR in patients undergoing clinically indicated

More information

2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD

2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD 2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic

More information

TAVR in 2020: What is Next!!!!

TAVR in 2020: What is Next!!!! TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures

More information

TAVR: Echo Measurements Pre, Post And Intra Procedure

TAVR: Echo Measurements Pre, Post And Intra Procedure 2017 ASE Florida, Orlando, FL October 10, 2017 8:00 8:25 AM 25 min TAVR: Echo Measurements Pre, Post And Intra Procedure Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate

More information

TAVR: Review of the Robust Data from Randomized Trials

TAVR: Review of the Robust Data from Randomized Trials TAVR: Review of the Robust Data from Randomized Trials Nicholas J. Ruggiero II, MD,FACP, FACC, FSCAI, FSVM, FCPP Director, Structural Heart Disease and Non-Coronary Interventions Director, Jefferson Heart

More information

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL DISCLOSURES I WILL BE DISCUSSING OFF-LABEL USAGE OF DEVICES RELATED TO TMVR OBJECTIVES

More information

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of

More information

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)

More information

2017 ESC/EACTS Guidelines for the management of valvular heart disease

2017 ESC/EACTS Guidelines for the management of valvular heart disease 2017 ESC/EACTS Guidelines for the management of valvular heart disease Prof. Fausto J. Pinto, FESC, FACC Immediate ESC Past President Head, Cardiology Dpt/ University Hospital Sta Maria-HPV University

More information

Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients?

Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients? Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients? David H. Adams, MD Cardiac Surgeon-in-Chief Mount Sinai Health System Marie Josée and Henry R. Kravis Professor and

More information

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan Degenerative MR is not Functional MR 2o - Functional MR : Ventricular Problem!!

More information

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention John N. Hamaty D.O. FACC, FACOI November 17 th 2017 I have no financial disclosures Primary Mitral

More information

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction

More information

William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA

William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA Mitral Valve Disease Today Mitral regurgitation is the most

More information

Percutaneous Valve in Native With and Without Mitral Valve Calcification: When To Go Hybrid

Percutaneous Valve in Native With and Without Mitral Valve Calcification: When To Go Hybrid Percutaneous Valve in Native With and Without Mitral Valve Calcification: When To Go Hybrid Deborah Tabachnick, MD Cardiac Surgeon The Heart Hospital Baylor Plano Baylor Scott & White Health Disclosures

More information

Journal of the Minneapolis Heart Institute Foundation

Journal of the Minneapolis Heart Institute Foundation Journal of the Minneapolis Heart Institute Foundation Informs and educates medical professionals about leading cardiovascular research conducted by MHIF and its partners Publishes clinical research, case

More information

The Evolving ACC-NCDR Programs: What you need to know for your practice

The Evolving ACC-NCDR Programs: What you need to know for your practice The Evolving ACC-NCDR Programs: What you need to know for your practice John S. Rumsfeld, MD PhD FACC Chief Science Officer and Chair, American College of Cardiology National Cardiovascular Data Registry

More information

Transcatheter Valve Therapies Update

Transcatheter Valve Therapies Update Providence Heart and Vascular Institute Transcatheter Valve Therapies Update Where In The H*@# Is All This Going??? Robert Hodson MD Medical Director, Providence Valve Center October 24, 2015 DISCLOSURES

More information

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of

More information

Valve Analysis and Pathoanatomy: THE MITRAL VALVE

Valve Analysis and Pathoanatomy: THE MITRAL VALVE : THE MITRAL VALVE Marc R. Moon, M.D. John M. Shoenberg Chair in CV Disease Chief, Cardiac Surgery Washington University School of Medicine, St. Louis, MO Secretary, American Association for Thoracic Surgery

More information

Valvular Heart Disease and Adult Congenital Intervention. A Pichard, MD. Director Cath Labs, Washington Hospital Center. Georgetown University.

Valvular Heart Disease and Adult Congenital Intervention. A Pichard, MD. Director Cath Labs, Washington Hospital Center. Georgetown University. Valvular Heart Disease and Adult Congenital Intervention. A Pichard, MD Director Cath Labs, Washington Hospital Center. ProfessorofMedicine (Cardiology), Georgetown University. Conflict of Interest Proctor

More information